Vascular targeting of antithrombotic agents

IUBMB Life

Volumn 63, Issue 8, 2011, Pages 632-639

  Carnemolla, Ronald ^a   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

drug design; endothelium; erythrocytes; plasminogen activators; thromboprophylaxis; thrombosis; vascular immunotargeting

Indexed keywords

ANTICOAGULANT AGENT; CD31 ANTIGEN; FIBRIN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE PLASMINOGEN ACTIVATOR THROMBIN; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; ERYTHROCYTE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; NEUROTOXICITY; NONHUMAN; REVIEW; THROMBOCYTE; THROMBOSIS; VEIN THROMBOSIS;

ANTITHROMBINS; DRUG DELIVERY SYSTEMS; HUMANS; THROMBOSIS;

EID: 79960776417     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.474     Document Type: Review

References (49)

1. Fuster, V., Badimon, L., Badimon, J. J., and, Chesebro, J. H., (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 326, 310-318.
2. Esmon, C. T., (2003) Inflammation and thrombosis. J. Thromb. Haemost. 1, 1343-1348.
3. McGuire, M., and, Dobesh, P. P., (2004) Therapeutic update on the prevention and treatment of venous thromboembolism. J. Pharm. Pract. 17, 289-307. (Pubitemid 39658286)
4. Ng, H. J., and, Crowther, M. A., (2006) New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin. Hematol. 43 (Suppl 1), S77-S83. (Pubitemid 43150504)
5. Lijnen, H. R., and, Collen, D., (1993) Development of thrombolytic agents. Biotecnol. Adv. 11, 115-130. (Pubitemid 23639936)
6. Heeremans, J. L., Prevost, R., Bekkers, M. E., Los, P., Emeis, J. J., Kluft, C., and, Crommelin, D. J., (1995) Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb. Haemost. 73, 488-494.
7. Leach, J. K., Patterson, E., and, O'Rear, E. A., (2004) Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators. J. Thromb. Haemost. 2, 1548-1555. (Pubitemid 40186169)
8. Kim, J. Y., Kim, J. K., Park, J. S., Byun, Y., and, Kim, C. K., (2009) The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30, 5751-5756.
9. Chung, T. W., Wang, S. S., and, Tsai, W. J., (2008) Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials 29, 228-237.
10. Carnemolla, R., Shuvaev, V. V., and, Muzykantov, V. R., (2010) Targeting antioxidant and antithrombotic biotherapeutics to endothelium. Semin. Thromb. Haemost. 26, 332-342.
11. Vyas, S. P., and, Vaidya, B., (2009) Targeted delivery of thrombolytic agents: role of integrin receptors. Expert Opin. Drug Deliv. 6, 499-508.
12. Runge, M. S., Bode, C., Matsueda, G. R., and, Haber, E., (1987) Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc. Natl. Acad. Sci. USA 84, 7659-7662.
13. Runge, M. S., Harker, L. A., Bode, C., Ruef, J., Kelly, A. B., et al. (1996) Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 94, 1412-1422. (Pubitemid 26307274)
14. Bode, C., Runge, M. S., Schönermark, S., Eberle, T., Newell, J. B., et al. (1990) Conjugation of antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 81, 1974-1980. (Pubitemid 20183847)
15. Peter, K., Graeber, J., Kipriyanov, S., Zewe-Welschof, M., Runge, M. S., et al. (2000) Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 101, 1158-1164. (Pubitemid 30146618)
16. Marsh, J. N., Senpan, A., Hu, G., Scott, M. J., Gaffney, P. J., et al. (2007) Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond.) 2, 533-543. (Pubitemid 47365128)
17. Sakharov, D. V., and, Rijken, D. C., (1995) Superficial accumulation of plasminogen during clot lysis. Circulation 92, 1883-1890.
18. Langer, H. F., and, Gawaz, M., (2008) Platelet-vessel wall interactions in atherosclerotic disease. Thromb. Haemost. 99, 480-486. (Pubitemid 351549284)
19. Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J., et al. (1999) Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from multicentre randomized trial: EPISTENT Investigators. Evaluation of Platelet IIb/IIIa for Stenting. Lancet 354, 2019-2024.
20. Bode, C., Meinhardt, G., Runge, M. S., Freitag, M., Nordt, T., et al. (1991) Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 84, 805-813.
21. DeMeyer, S. F., Vanhoorelbeke, K., Broos, K., Salles, I. I., and, Deckmyn, H., (2008) Antiplatelet drugs. Br. J. Haemotol. 142, 515-528. (Pubitemid 352020216)
22. Rossi, L., Serafini, S., Pierigé, F., Antonelli, A., Cerasi, A., et al. (2005) Erythrocyte-based drug delivery. Expert Opin Drug Deliv. 2, 311-322. (Pubitemid 41130885)
23. Murciano, J. C., Medinilla, S., Eslin, D., Atochina, E., Cines, D. B., et al. (2003) Prophylatic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol. 21, 891-896. (Pubitemid 36936194)
24. Ganguly, K., Krasik, T., Medinilla, S., Bdeir, K., Cines, D. B., et al. (2005) Blood clearance and activity of erythrocyte-coupled fibrinolytics. J. Pharmacol. Exp. Ther. 312, 1106-1113. (Pubitemid 40293770)
25. Ganguly, K., Goel, M. S., Krasik, T., Bdeir, K., Diamond, S. L., et al. (2006) Fibrin affinity of erythrocyte-coupled tissue type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J. Pharmacol. Exp. Ther. 316, 1130-1136. (Pubitemid 43348697)
26. Ganguly, K., Murciano, J. C., Westrick, R., Leferovich, J., Cines, D. B., et al. (2007) The glycocalyx protects erythrocyte-bound tissue-type plasminogen activators from enzymatic inhibition. J. Pharmacol. Exp. Ther. 321, 158-164. (Pubitemid 46456958)
27. Murciano, J. C., Higazi, A. A., Cines, D. B., and, Muzykantov, V. R., (2009) Soluble urokinase receptor conjugated to red blood cells binds latent pro-urokinase and alters its functional profile. J. Control. Release 139, 190-196.
28. Danielyan, K., Ganguly, K., Ding, B. S., Atochin, D., Zaitsev, S., et al. (2008) Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation 118, 1442-1449.
29. Armstead, W. M., Ganguly, K., Kiessling, J. W., Chen, X. H., Smith, D. H., et al. (2009) Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J. Cereb. Blood Flow Metab. 29, 1463-1474.
30. Armstead, W. M., Ganguly, K., Riley, J., Kiessling, J. W., Cines, D. B., et al. (2010) Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig. Pediatr Crit Care Med., in press.
31. Stein, S. C., Ganguly, K., Belfield, C. M., Xu, X., Swanson, E. W., et al. (2009) Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J. Neurotrauma 26, 1585-1592.
32. Zaitsev, S., Danielyan, K., Murciano, J. C., Ganguly, K., Krasik, T., et al. (2006) Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 108, 1895-1902. (Pubitemid 44403687)
33. Zaitsev, S., Spitzer, D., Murciano, J. C., Ding, B. S., Tliba, S., et al. (2010) Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J. Pharmacol. Exp. Ther. 332, 1022-1031.
34. Barinka, C., Parry, G., Callahan, J., Shaw, D. E., Kuo, A., et al. (2006) Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J. Mol. Biol. 363, 482-495. (Pubitemid 44472493)
35. Yang, W. P., Goldstein, J., Procyk, R., Matsueda, G. R., and Shaw, S. Y., (1994) Design and evaluation of a thrombin-activable plasminogen activator. Biochemistry 33, 606-612.
36. Zaitsev, S., Spitzer, D., Murciano, J. C., Ding, B. S., Tliba, S., et al. (2010) Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 115, 5241-5248.
37. Muzykantov, V. R., Barnathan, E. S., Atochina, E. N., Kuo, A., Danilov, S. M., et al. (1996) Targeting to antibody-conjugated plasminogen activators to the pulmonary vasculature. J. Pharmacol. Exp. Ther. 279, 1026-1034. (Pubitemid 27166881)
38. Murciano, J. C, Harshaw, D. W., Ghitescu, L., Danilov, S. M., and, Muzykantov, V. R., (2001) Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries. Am. J. Respir. Crit. Care Med. 164, 1295-1302. (Pubitemid 33052266)
39. Ding, B. S., Dziubla, T., Shuvaev, V. V., Muro, S., and, Muzykantov, V. R., (2006) Advanced drug delivery systems that target the vascular endothelium. Mol. Interv. 6, 98-112.
40. Muro, S., Dziubla, T., Qiu, W., Leferovich, J., Cui, X., (2006) Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharm. Exp. Ther. 317, 1161-1169. (Pubitemid 43764121)
41. Ding, B. S., Gottstein, C., Grunow, A., Kuo, A., Ganguly, K., et al. (2005) Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106, 4191-4198. (Pubitemid 41775926)
42. Scherpereel, A., Rome, J. J., Wiewrodt, R., Watkins, S. C., Harshaw, D. W., et al. (2002) Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J. Pharmacol. Exp. Ther. 300, 777-786. (Pubitemid 34164979)
43. Garnacho, C., Dhami, R., Simone, E., Dziubla, T., Leferovich, J., et al. (2008) Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J. Pharm. Exp. Ther. 325, 400-408. (Pubitemid 351574785)
44. Muzykantov, V. R., Christofidou-Solomidou, M., Balyasnikova, I., Harshaw, D. W., Schultz, L., et al. (1999) Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl. Acad. Sci. USA 96, 2379-2384. (Pubitemid 29117923)
45. Muro, S., Wiewrodt, R., Thomas, A., Koniaris, L., Albelda, S. M., et al. (2003) A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116 (Part 8), 1599-1609. (Pubitemid 36527505)
46. Almenar-Queralt, A., Duperray, A., Miles, L. A., Felez, J., and, Altieri, D. C., (1995) Apical topography and modulation of ICAM-1 expression on activated endothelium. Am. J. Pathol. 147, 1278-1288.
47. Murciano, J. C., Muro, S., Koniaris, L., Christofidou-Solomidou, M., Harshaw, D. W., et al. (2003) ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 101, 3977-3984. (Pubitemid 36857875)
48. Danielyan, K., Ding, B. S., Gottstein, C., Dines, D. B., and, Muzykantov, V. R., (2007) Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates post-ischemic brain edema. J. Pharmacol. Exp. Ther. 321, 947-952. (Pubitemid 46762681)
49. Ding, B. S., Hong, N., Murciano, J. C., Ganguly, K., Gottstein, C., et al. (2008) Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 111, 1999-2006. (Pubitemid 351451510)